BioNexus Gene Lab Corp (BGLC) shareholders
Close on Nov 13, 2026Market cap $2.41MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Soo Kow Lai Joint filing with Kim Hai Wong (5.90%), Liong Tai Tan (5.86%) and 2 more | 1,250,001 | 7.03% | 13D (active) | Dec 11, 2023 |
| Fidelion Diagnostics Pte. Ltd. Joint filing with Molecule Bio LLC (13.40%), Xiao Ling (13.40%) and 1 more | 392,329 | 13.40% | 13G (passive) | Nov 28, 2025 |
| Tan Lee Su-Leng | 338,709 | 11.50% | 13D (active) | Aug 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BGLC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 14,283 | 0.49% | $27.00K | New | 0.00% |
| UBS Group AG | 101 | 0.00% | $197 | −130 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $2 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3 | 0M | 0.5% | 2 / 0 | 1 / 1 | 0M | 0M |
| Q1 2026 | 2 | 0M | 0.0% | 2 / 0 | 0 / 1 | 0M | 0M |
| Q4 2025 | 1 | 0M | 1.6% | 0 / 1 | 0 / 1 | 0M | 0M |
| Q3 2025 | 2 | 0M | 0.8% | 1 / 0 | 1 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.3% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
2 funds held BGLC in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BGLC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 2,368 | 0.08% | $5.49K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 3 | 0.00% | $6 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lee Su-Leng Tan | Chief Executive Officer, Director, 10% owner | 338,709 | 11.55% | Aug 14, 2026 |
| Set Fui Chong | Chief Financial Officer | 96,774 | 3.30% | Aug 14, 2026 |
| Jook Yuen Low | Director | 17,390 | 0.59% | Aug 14, 2026 |
| Abdul Hamid Muhammad Azrul Bin | Director | 32,258 | 1.10% | Aug 14, 2026 |
| Chee Keong Yap | Director | 32,258 | 1.10% | Aug 14, 2026 |
| Diagnostics Pte. Ltd. Fidelion | – | 392,329 | 13.37% | Aug 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Set Fui Chong Chief Financial Officer | Aug 13, 2026 | Award | +96,774 | – | – | 96,774 |
| Jook Yuen Low Director | Aug 13, 2026 | Award | +16,129 | – | – | 17,390 |
| Abdul Hamid Muhammad Azrul Bin Director | Aug 13, 2026 | Award | +32,258 | – | – | 32,258 |
| Lee Su-Leng Tan Chief Executive Officer, Director, 10% owner | Aug 13, 2026 | Award | +338,709 | – | – | 338,709 |
| Chee Keong Yap Director | Aug 13, 2026 | Award | +32,258 | – | – | 32,258 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioNexus Gene Lab's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,115 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?